<DOC>
	<DOCNO>NCT01874405</DOCNO>
	<brief_summary>Iron overload lead cause morbidity mortality transfusion-dependent patient . Deferasirox promise iron chelator agent several clinical scenario . The investigator propose retrospective study ( chart review ) evaluate comprehensive iron overload management transfusion-dependent patient treat deferasirox 5-10 year real clinical practice setting .</brief_summary>
	<brief_title>Retrospective Evaluation Adult Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Transfusion dependent patient ( &gt; 2 year ) ; Ongoing deferasirox therapy study period ; â‰¥ 2 Magnetic Resonance scan ( one baseline least one post baseline per clinical need ) study period ( criteria mandatory patient undergoing endocrine subanalysis participate cardiac analysis ) ; Available medical history include relevant clinical laboratory data ( e.g serum ferritin , liver function test , renal function test , endocrine parameter ) baseline start deferasirox treatment Non transfusion dependent patient ; Other chelation therapy deferasirox ; Absence complete medical history specify</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Iron overload</keyword>
	<keyword>thalassaemia</keyword>
	<keyword>deferasirox</keyword>
	<keyword>magnetic resonance</keyword>
	<keyword>endocrine function</keyword>
</DOC>